SecBot SecBot
25-NSE ·Filed Apr 23, 2026

DAWN

Day One Biopharmaceuticals, Inc.
NEUTRAL
Impact 9/10
Horizonimmediate Processed6mo ago SEC0001354457-26-000366
Notable filing: 25-NSE
Actionable Insight • Neutral

Shares will cease trading and be removed from Nasdaq; investors should expect final settlement from the acquisition. No further public filings or trading activity will occur.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK AT ENTRY AT T+1
Entry
$21.53
T+0 close · Apr 23, 2026 · via day close
Latest settled
0.00%
T+1 · $21.53
Vs SPY
−0.78%
α at T+1
Next horizon
T+5
due 7mo ago
  1. T+0 · Apr 23 $21.53entry
  2. T+1 · 7mo ago 0.00%α −0.78% · $21.53
  3. T+5 · due 7mo ago Pending
  4. T+20 · due 6mo ago Pending
  5. T+60 · due 4mo ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Nasdaq has filed Form 25 to delist Day One Biopharmaceuticals (DAWN) common stock, effective immediately, following the company's acquisition by Servier Pharmaceuticals. This is a procedural step confirming the completion of the take-private transaction.

Key Facts

  • Form 25-NSE filed by Nasdaq to delist DAWN common stock
  • Effective date of delisting is 2026-04-23
  • Follows the previously announced acquisition of Day One by Servier Pharmaceuticals
  • Merger closed after Servier secured 85.34% of shares via tender offer
  • DAWN is no longer a publicly traded company

Financial Impact

Entire company acquired for $2.5 billion in all-cash transaction

marketCapsharesOutstandingliquidity

Risk Factors

  • None for public shareholders, transaction is complete and fully settled
  • Loss of liquidity for former shareholders who did not tender

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
25-NSE Filing (Primary)0001354457-26-000366
Document: 0001354457-26-000366-index-headers.html0001354457-26-000366
Document: 0001354457-26-000366-index.html0001354457-26-000366
Document: 0001354457-26-000366.txt0001354457-26-000366

Track record

6 reports on DAWN

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. May 4, 202628w ago 15-12G Neutral 5/10 No price data
  2. Apr 23, 202629w ago 25-NSE Neutral 9/10 Viewing Entry $21.53 No price data
  3. Apr 23, 202629w ago 8-K Neutral 9/10 Entry $21.53 No price data
  4. Apr 17, 202630w ago 10-K/A Neutral 4/10 Entry $21.48 No price data
  5. Mar 6, 202636w ago Press Release Bullish 9/10 Entry $21.20 to $21.46 ▲ +1.23% +3.27% vs SPY
  6. Feb 24, 202637w ago 8-K Bullish 8/10 Entry $10.92 to $21.37 ▲ +95.79% +101.02% vs SPY
Showing 6 of 6

US Market Status

Market Closed · Opens in 5h 59m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 23, 2026